Dec

22

Category: Beauty | Date : December 22, 2014

You r & ecirc ; vez a hairstyle r & eacute; tro, Type 50 ‘s, but do not know how to do it ? Do not panic, Fabien Provost explains gestures cl & eacute; s for a bun r & eacute; tro of ann & eacute; es 50 well r & eacute; ussi.

The bun of ann & eacute; es 50 is id & eacute; alement a fried & eacute hair base e or corrugated & eacute; e.

To do this, worked texture your hair & agrave ; Using your old curlers or your iron & agrave ; curl.

The id & eacute; e & eacute; as to maintain motion and flexibility in your hair.

The principle is simple, QC & ecirc ; pez your lengths m & egrave ; che per m & egrave ; che, by painting the tip to the root.

In this way & ccedil ; there, you can fix your dé hairpins with much more ease & eacute;.

Bring back then int & eacute; gralit & eacute; your hair to the rear & egrave ; re, and down.

Needless to press them, the goal dé as to obtain a soft and voluptuous made.

By reducing your length ball in the palm of your hand, then fasten the bun & agrave ; Using your & eacute; hairpins & agrave ; hair.

Then put your m & egrave ; ches rebels to the rear & egrave ; re always & agrave ; Using your fid & egrave ; the & eacute; hairpins.

Dec

22

Category: Science | Date : December 22, 2014

People with ob & eacute; sit & eacute; will soon OCIRC & ; t b & eacute; n & eacute; acquirable a new treatment that could help them & agrave ; lose weight.

This is m & eacute; dicament combining two mol & eacute; d & eacute particles j & agrave ; known, bupropion and naltrexone.

Produced by the laboratory am dé Rican Orexigen Therapeutics, is homologu & eacute; to & Eacute ; the United States since last September, after & egrave ; s several years & eacute; es of h & eacute; sitation li & eacute; es & agrave ; fear of dé = increasing heart risks.

The committee & eacute; of m & eacute; & agrave drugs ; Human Use of the European Agency & eacute; enne of m & eacute; dicament therefore has recommended approving its authorization on the market & eacute;.

The green light should dé sormais & ecirc ; be approved & eacute; by the European Commission & eacute; enne before be marketed in each & Eacute ; Member State.

The Mysimba will be available by prescription and must & ecirc ; be r & eacute; serv & eacute; & agrave ; ob & egrave adult, his or overweight, having surcro & icirc ; t one or more other risk factors such as hypertension Art & eacute; rial, a diab & egrave ; type you two or rate & eacute; lev & eacute; Cholesterol & eacute; rol.

Among ind é effects of this potential sirables m & eacute; dicament, the agency mentions gastrointestinal disorders or li & eacute; s to the system & egrave ; central nervous.

In addition, it recognizes & icirc ; t as & quot; There is uncertainty regarding the r & eacute; & agrave cardiovascular results ; long term & quot;.

But she adds that the r & eacute; interm results & eacute; mediate a clinical trial & quot; are reassuring regarding the risk of serious cardiovascular disease & quot;.

& quot; R & eacute; major & quot progression ; for s & eacute; SAFETY & eacute; patient.

This dé decision has imm & eacute; & diately entered icirc ; n & eacute; bright r & eacute; action Prescrire that speaks of & quot; r & eacute; major & quot progression ; for s & eacute; SAFETY & eacute; patient.

It highlights the famous & quot; & quot ;, cardiovascular uncertainties mentioned & eacute; es European Agency & eacute; enne.

The journal ind & eacute; pending advanced nature of bupropion is dé also call & eacute; & quot; Amf & eacute; butamone & quot; and whose structure is similar to that of d & eacute; riv & eacute; s amph & eacute; taminiques.

She also points out that the m & ecirc ; my agency has withdrawn & eacute; authorizing the placing on the market & eacute; several anorexig & egrave ; nes for the sake of health & eacute; Public in 2000.

A fa & ccedil ; we show its incoh & eacute; ences..

It must be said that the history of m & eacute; drugs destiny & eacute; s & agrave ; fight against ob & eacute; sit & eacute; is jalonn & eacute; e of many problems & egrave ; my.

In 2009, sibutramine, a anorexig & egrave ; not structurally li & eacute; to amph & eacute; stamens, a & eacute; also disappeared from the market & eacute; European & eacute; in, l & agrave ; again because of serious side effects.

This antidiab & eacute; tick, widely prescribed for its properties & eacute; t & eacute; s appetite suppressants, finally & eacute; t & eacute; withdrawn & eacute; of the market & eacute; fran & ccedil ; ais in 2009.

& Agrave ; cause serious l & eacute; sions of heart valves, the Mediator may ecirc & ; & agrave be responsible ; Long-term d & eacute; c & egrave ; s whose number is tr & egrave ; s hard & agrave ; dé evaluate.

Regarding Mysimba, European Agency & eacute; enne explains that four dé studies have shown & eacute; a decrease in weight & quot; clinically relevant & quot; in the groups b & eacute; n & eacute; fici & eacute; the m & eacute; & dicament compared agrave ; those with re & ccedil ; u placebo.

And the latter is arr & ecirc ; t & eacute; if the patient failed & agrave ; lose at least 5% of its weight.